You are here

Clinical trials

Primary tabs

This Clinical Trials listing details all currently-active CML trials. Please contact us to suggest any missing trials.
Always discuss your trial suitability with your clinician or oncologist, remembering to give them the trial investigator's email address, which can be found on the official trial pages we link to.

Recruiting: unknown
Trial period: 1 December 2012 to 31 January 2019

Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib

Treatments: nilotinib
Recruiting: 1 June 2012 to 30 June 2016
Trial period: 1 December 2012 to 31 January 2019

European Stop Tyrosine Kinase Inhibitor Study

Recruiting: 1 January 2014 to 1 October 2015
Trial period: 1 December 2013 to 31 December 2017

De-Escalation & Stopping Treatment of Imatinib, Nilotinib or sprYcel in CML

Treatments: imatinib, nilotinib, dasatinib
Recruiting: 26 May 2015 to 1 October 2015
Trial period: 1 December 2013 to 1 January 2019

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

Treatments: nilotinib
Recruiting: 1 May 2012 to 31 October 2018
Trial period: 1 December 2013 to 1 January 2019

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Treatments: imatinib, nilotinib, dasatinib
Recruiting: 1 May 2012 to 31 October 2018
Trial period: 1 December 2013 to 1 January 2019

Randomized Phase III Study to Assess the Effect of Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML

Treatments: nilotinib
Recruiting: 1 February 2014 to 1 May 2020
Trial period: 1 February 2014 to 1 May 2020

Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response.

Treatments: dasatinib
Recruiting: 1 June 2014 to 1 May 2020
Trial period: 1 June 2014 to 1 May 2020

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Treatments: bosutinib